// App-Quantinova.ai

TCT-668 : Everolimus Eluting Stents Versus First Generation Drug Eluting Stents (Sirolimus or Paclitaxel) for Treatment of Drug-Eluting Stent In-Stent Restenosis

Researchers

Presenter

  • Sachin Goel

Principal Investigators

  • Wael El-Mallah

  • Mobolaji Ige

  • Supriya Gupta

  • E Murat Tuzcu

  • Stephen Ellis

  • Samir Kapadia

Medical Centers

  • Cleveland Clinic, Cleveland, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Myocardial infarction

  • Restenosis

  • Renal insufficiency

  • Dyslipidemia

  • Venous thrombosis

  • Diabetes

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

  • Paclitaxel

  • Rapacan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved